Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma
Standard
Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. / Stein, Barbara; Schrader, Andres Jan; Wegener, Gerd; Seidel, Christoph; Kuczyk, Markus A; Steffens, Sandra.
In: BMC CANCER, Vol. 13, 06.03.2013, p. 101.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma
AU - Stein, Barbara
AU - Schrader, Andres Jan
AU - Wegener, Gerd
AU - Seidel, Christoph
AU - Kuczyk, Markus A
AU - Steffens, Sandra
PY - 2013/3/6
Y1 - 2013/3/6
N2 - BACKGROUND: To analyse the prognostic significance of preoperative C-reactive protein (CRP) serum level in patients with upper urinary tract urothelial carcinoma (UUT-UC).METHODS: We evaluated 158 UUT-UC patients who had undergone surgery in the University Hospital of Hannover (MHH). 143 (89.4%) suffered from cancer in the renal pelvis, 13 (8.1%) patients presented with tumour located in the ureter. A preoperative CRP value was available for 115 patients. The mean (median) follow-up for these patients was 28.3 (15.1) months.RESULTS: The median (mean) CRP value of all evaluable patients was 10.0 (40.7) mg/l. The CRP-level, stratified into two subgroups (CRP ≤5 vs. >5 mg/l), correlated significantly with muscle invasive tumour stage (36.4 vs. 78.9%; p<0.001), the risk of presenting nodal disease (4.5 vs. 26.8%; p=0.002) and distant metastasis (2.3 vs. 16.9%; p<0.016). The Kaplan-Meier 5-year cancer specific survival (CSS) rates were 54.2 and 26.4% for patients with preoperative CRP levels ≤ and >5 mg/l, respectively (p<0.006). Next to age and the presence of metastasis, multivariate analysis also identified CRP as a continuous variable as an independent prognosticator for CSS.CONCLUSIONS: A high preoperative serum CRP level is associated with locally advanced and metastatic disease in patients with UUT-UC. Its routine use could allow better risk stratification and risk-adjusted follow-up of UUT-UC patients.
AB - BACKGROUND: To analyse the prognostic significance of preoperative C-reactive protein (CRP) serum level in patients with upper urinary tract urothelial carcinoma (UUT-UC).METHODS: We evaluated 158 UUT-UC patients who had undergone surgery in the University Hospital of Hannover (MHH). 143 (89.4%) suffered from cancer in the renal pelvis, 13 (8.1%) patients presented with tumour located in the ureter. A preoperative CRP value was available for 115 patients. The mean (median) follow-up for these patients was 28.3 (15.1) months.RESULTS: The median (mean) CRP value of all evaluable patients was 10.0 (40.7) mg/l. The CRP-level, stratified into two subgroups (CRP ≤5 vs. >5 mg/l), correlated significantly with muscle invasive tumour stage (36.4 vs. 78.9%; p<0.001), the risk of presenting nodal disease (4.5 vs. 26.8%; p=0.002) and distant metastasis (2.3 vs. 16.9%; p<0.016). The Kaplan-Meier 5-year cancer specific survival (CSS) rates were 54.2 and 26.4% for patients with preoperative CRP levels ≤ and >5 mg/l, respectively (p<0.006). Next to age and the presence of metastasis, multivariate analysis also identified CRP as a continuous variable as an independent prognosticator for CSS.CONCLUSIONS: A high preoperative serum CRP level is associated with locally advanced and metastatic disease in patients with UUT-UC. Its routine use could allow better risk stratification and risk-adjusted follow-up of UUT-UC patients.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers, Tumor
KW - C-Reactive Protein
KW - Carcinoma
KW - Female
KW - Humans
KW - Kaplan-Meier Estimate
KW - Kidney Neoplasms
KW - Kidney Pelvis
KW - Male
KW - Middle Aged
KW - Multivariate Analysis
KW - Preoperative Period
KW - Prognosis
KW - Ureteral Neoplasms
U2 - 10.1186/1471-2407-13-101
DO - 10.1186/1471-2407-13-101
M3 - SCORING: Journal article
C2 - 23497335
VL - 13
SP - 101
JO - BMC CANCER
JF - BMC CANCER
SN - 1471-2407
ER -